登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002737 证券简称：葵花药业 证券编号：2025-077 葵花药业集团股份有限公司 关于注销全资子公司的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 二、注销子公司进展情况 公司于近日办理完成葵花大药房的注销登记相关事项，并取得五常市市场监督管理局下发的注销登记通 知书。 此次注销全资子公司事项不会对公司整体财务、经营情况产生重大影响，不存在损害公司及全体股东， 特别是中小股东合法权益的情形。 三、备查文件 1、注销登记通知书 特此公告。 葵花药业集团股份有限公司 董事会 一、事项概述 葵花药业集团股份有限公司（以下简称"公司"）于2025年7月25日召开第五届董事会第八次会议，审议 通过《关于部分子（孙）公司注销及吸收合并的议案》，公司基于优化投资控股体系，缩短管理链条， 实现资源有效整合，降低成本集约发展需求，决定注销全资子公司黑龙江葵花大药房有限公司（以下简 称"葵花大药房"）。 上述注销子公司事项的具体内容详见公司于2025年7月26日披露于《证券日报》、《上海证券报》及巨 潮 ...

一、事项概述 证券代码：002737 证券简称：葵花药业 证券编号：2025-077 葵花药业集团股份有限公司 关于注销全资子公司的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 1、注销登记通知书 1 特此公告。 葵花药业集团股份有限公司 葵花药业集团股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日召开 第五届董事会第八次会议，审议通过《关于部分子（孙）公司注销及吸收合并的 议案》，公司基于优化投资控股体系，缩短管理链条，实现资源有效整合，降低 成本集约发展需求，决定注销全资子公司黑龙江葵花大药房有限公司（以下简称 "葵花大药房"）。 上述注销子公司事项的具体内容详见公司于 2025 年 7 月 26 日披露于《证券 日报》、《上海证券报》及巨潮资讯网（http:www.cninfo.com.cn）的相关公告 （公告编号 2025-041、2025-043）。 二、注销子公司进展情况 公司于近日办理完成葵花大药房的注销登记相关事项，并取得五常市市场监 督管理局下发的注销登记通知书。 此次注销全资子公司事项不会对公司整体财务、经营情 ...

关于2022年员工持股计划股份出售完毕暨终止的公告 证券代码：002737 证券简称：葵花药业 公告编号：2025-076 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 葵花药业集团股份有限公司 一、本次员工持股计划的基本情况 公司于2022年8月23日召开第四届董事会第二十一次会议、第四届监事会第十四次会议，并于2022年9月 9日召开2022年第二次临时股东大会，审议通过了《关于公司2022年员工持股计划（草案）及其摘要的 议案》及相关议案。 2022年10月28日，公司收到中国证券登记结算有限责任公司下发的《证券过户登记确认书》，"葵花药 业集团股份有限公司回购专用证券账户"所持有的2,950,060股公司股票已于2022年10月27日非交易过户 至"葵花药业集团股份有限公司-2022年员工持股计划"，过户股份数量占公司总股本的0.51%，过户价格 为7.50元/股。 葵花药业集团股份有限公司（以下简称"公司"或"葵花药业"）于2022年8月实施公司2022年员工持股计 划，具体内容详见公司于2022年 ...

（文章来源：证券日报） 证券日报网讯 11月24日晚间，葵花药业发布公告称，截至公告日，公司2022年员工持股计划所持有的 公司股票共计2，950，060股已通过二级市场以集中竞价交易方式全部出售完毕，占公司目前总股本的 0.51%。根据公司2022年员工持股计划的相关规定，本次员工持股计划实施完毕并提前终止，后续将进 行财产清算和相关分配等工作。本次员工持股计划实施期间，公司严格遵守市场交易规则，遵守中国证 监会、深圳证券交易所关于信息敏感期不得买卖股票的规定，未利用任何内幕信息进行交易。 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-076 葵花药业集团股份有限公司 关于 2022 年员工持股计划股份出售完毕暨终止的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"葵花药业"）于 2022 年 8 月实施公司 2022 年员工持股计划，具体内容详见公司于 2022 年 8 月 24 日、 2022 年 9 月 10 日刊登在巨潮资讯网上的相关公告。目前，公司 2022 年员工持 股计划所持有的公司股份已全部售出完毕，根据《关于上市公司实施员工持股计 划试点的指导意见》、《葵花药业集团股份有限公司 2022 年员工持股计划（草 案）》等相关规定，现将相关情况公告如下： 一、本次员工持股计划的基本情况 公司于 2022 年 8 月 23 日召开第四届董事会第二十一次会议、第四届监事会 第十四次会议，并于 2022 年 9 月 9 日召开 2022 年第二次临时股东大会，审议通 过了《关于公司 2022 年员工持股计划（草案）及其摘要的议案》及相关议案。 2022 年 10 月 28 ...

Core Insights - On November 20, 2023, Kewah Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 30.31 million yuan [1] - The company reported a financing buy-in of 3.57 million yuan and a net financing buy of 1.38 million yuan on the same day [1] - As of November 20, the total margin balance for Kewah Pharmaceutical was 140 million yuan, indicating a low financing balance compared to the past year [1] Financing and Margin Data - Kewah Pharmaceutical's financing buy-in on November 20 was 3.57 million yuan, with a current financing balance of 138 million yuan, accounting for 1.60% of the circulating market value [1] - The company’s margin trading showed a repayment of 1,200 shares with no shares sold, resulting in a margin balance of 1.49 million yuan, which is also low compared to the past year [1] Company Overview - Kewah Pharmaceutical Group Co., Ltd. was established on September 7, 2005, and listed on December 30, 2014 [1] - The company specializes in the research, production, and sales of various traditional Chinese medicines and chemical drugs, with revenue composition as follows: traditional Chinese medicine 64.83%, chemical drugs 26.56%, nutritional health products 8.22%, and others 0.39% [1] Financial Performance - For the period from January to September 2025, Kewah Pharmaceutical reported a revenue of 1.684 billion yuan, a year-on-year decrease of 43.24%, and a net profit attributable to shareholders of -33.54 million yuan, a year-on-year decrease of 105.72% [2] Dividend Information - Since its A-share listing, Kewah Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Kewah Pharmaceutical had 53,000 shareholders, with an average of 11,018 circulating shares per person [2] - The top ten circulating shareholders include various ETFs, with notable changes in holdings among them [3]

Core Insights - The article highlights the successful participation of Sunflower Group at the 91st National Pharmaceutical Trade Fair and China International Health Nutrition Expo in Nanjing, where it showcased its brand "Wen Dong Fang" and won the "Innovation Pioneer - Industrial Enterprise Award" [3] Group 1: Company Achievements - Sunflower Group's health segment, in collaboration with its liquor division, has gained significant attention for its cross-industry innovation approach, emphasizing "brewing with a pharmaceutical heart" [3] - The "Wen Dong Fang" liquor has been well-received due to its pharmaceutical-grade quality control standards and the integration of traditional techniques with modern technology, leading to high demand and successful sales during the event [5] Group 2: Product Quality and Innovation - The "Wen Dong Fang" team undertook a three-year journey to select high-quality chestnuts from the "Hometown of Chinese Chestnuts" in Qianxi, Hebei, ensuring that each chestnut meets pharmaceutical-grade standards, with iron content in century-old trees being 2.1 times that of younger trees [9] - The production process combines traditional chestnut liquor brewing techniques with modern biological extraction technology, enhancing the absorption of herbal active ingredients while maintaining a low yield of 1 jin of liquor from 12 jin of chestnuts [9] Group 3: Market Positioning and Recognition - "Wen Dong Fang" is recognized as a pioneer in herbal chestnut liquor, catering to diverse consumer needs with products like "Wen Dong Fang No. 6" and "Wen Dong Fang No. 9," designed for casual drinking and gifting [9] - The brand has received authoritative recognition from industry experts and has been featured in a CCTV program, enhancing its credibility and public awareness [9][10]

Group 1 - The fifth meeting of the board of directors of Kew Flower Pharmaceutical Group Co., Ltd. was held on November 18, 2025, via telecommunication voting, with all nine directors participating [2][4]. - The board approved a proposal for product research and development, allocating up to 50 million yuan for projects including traditional Chinese medicine and generic drug development [3][5]. - The decision was made with unanimous support, receiving 9 votes in favor and no opposition or abstentions [4]. Group 2 - The meeting was convened by the chairwoman, Ms. Guan Yuxiu, and the notice and agenda were sent out on November 13, 2025 [2]. - The board's resolutions are valid and do not require submission to the shareholders' meeting for approval [5]. - The company ensures the accuracy and completeness of the information disclosed in the announcement [1].

Core Viewpoint - The company, Kewang Pharmaceutical, has a diverse product portfolio covering various therapeutic areas, including pediatric and adult respiratory medications, indicating a strong presence in the respiratory and general health sectors [1] Product Coverage - The company's products span several treatment areas: children's medications, digestive system, respiratory and cold system, rheumatology, cardiovascular system, gynecology, and general health [1] - In the respiratory and cold treatment area, the company offers a range of pediatric medications, including: - Xiaoer Feire Kechuan Oral Liquid/Granules - Xiaoer Huatan Zhike Granules - Xiaoer Keshuan Ling - Xiaoer Chaigui Antipyretic Granules - Ibuprofen Suspension Drops/Liquid - Roxithromycin Granules - Azithromycin Dry Suspension [1] - For adult respiratory medications, the company provides: - Ganmaoling Capsules/Granules - Compound Acetaminophen and Amantadine Capsules/Granules/Tablets - Ambroxol Hydrochloride Oral Solution - Roxithromycin Dispersible Tablets/Capsules - Pudilan Anti-inflammatory Tablets - Compound Honeysuckle Granules - Azithromycin Capsules/Tablets [1]

Core Points - The company, Kew Flower Pharmaceutical Group Co., Ltd., announced a board resolution on November 18, 2025, to allocate up to 50 million yuan for product research and development, focusing on traditional Chinese medicine, generic drug consistency evaluation projects, and expanding indications for existing products [1][2] - The board meeting was conducted via telecommunication, with all 9 participating directors voting in favor of the proposal, indicating unanimous support for the R&D initiatives [1] - The R&D investment aims to optimize the product structure and enhance the company's core competitiveness, reinforcing its long-term development strategy in the pharmaceutical sector [2] Summary by Categories R&D Investment - The company plans to invest no more than 50 million yuan in R&D, targeting three main areas: traditional Chinese medicine, generic drug consistency evaluation, and expanding indications for existing products [1] - This investment is intended to enrich the product pipeline and strengthen the company's long-term growth potential [1][2] Board Meeting Details - The fifth board's thirteenth meeting was held on November 18, 2025, with all 9 directors participating and voting unanimously in favor of the R&D proposal [1] - The decision falls within the board's authority and does not require shareholder approval, allowing management to control the project’s progress [1] Strategic Focus - Kew Flower Pharmaceutical continues to focus on its core pharmaceutical business, with this R&D funding expected to enhance its position in the innovation of traditional Chinese medicine and the quality improvement of generic drugs [2]